Back to top
more

Nyxoah (NYXH)

(Real Time Quote from BATS)

$7.40 USD

7.40
32,955

-0.06 (-0.80%)

Updated Aug 6, 2025 10:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 246)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nyxoah (NYXH) delivered earnings and revenue surprises of -28.57% and 29.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Claritev Corporation (CTEV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Claritev Corporation (CTEV) delivered earnings and revenue surprises of -55.91% and 7.68%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Health Catalyst (HCAT) Q1 Earnings Meet Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of 0% and 0.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 171.43% and 3.06%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nyxoah SA (NYXH) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nyxoah (NYXH) delivered earnings and revenue surprises of 2% and 40.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Phreesia (PHR) delivered earnings and revenue surprises of 42.11% and 0.71%, respectively, for the quarter ended January 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Schrodinger (SDGR) delivered earnings and revenue surprises of -57.14% and 5.79%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Hims & Hers Health (HIMS) Surges 27.7%: Is This an Indication of Further Gains?

by Zacks Equity Research

Hims & Hers Health (HIMS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Nyxoah SA (NYXH) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nyxoah (NYXH) delivered earnings and revenue surprises of -47.83% and 17.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Privia Health (PRVA) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Privia Health (PRVA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Nyxoah SA (NYXH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Nyxoah (NYXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Nyxoah SA (NYXH) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nyxoah (NYXH) delivered earnings and revenue surprises of -2.22% and 56.88%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Clover Health Investments, Corp. (CLOV) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 125% and 5.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CareCloud, Inc. (CCLD) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

CareCloud (CCLD) delivered earnings and revenue surprises of 93.75% and 2.22%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Privia Health (PRVA) Misses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Privia Health (PRVA) delivered earnings and revenue surprises of -60% and 4.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inspire Medical Systems (INSP) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inspire (INSP) delivered earnings and revenue surprises of 46.03% and 1.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Nyxoah SA (NYXH) delivered earnings and revenue surprises of 0% and 2.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 13.33% and 10.67%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nextgen Healthcare (NXGN) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 24% and 0.20%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nyxoah SA (NYXH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nyxoah SA (NYXH) delivered earnings and revenue surprises of -8.89% and 15.64%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pulmonx Corporation (LUNG) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 8.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Nyxoah SA (NYXH) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Nyxoah SA (NYXH) delivered earnings and revenue surprises of -32.43% and 61.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 21.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Syneos Health (SYNH) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Syneos Health (SYNH) delivered earnings and revenue surprises of 11.94% and 6.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Senseonics Holdings (SENS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Senseonics (SENS) delivered earnings and revenue surprises of 0% and 35.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?